Colin Wernsdoerfer

Colin Wernsdoerfer has a diverse and extensive work experience in the medical field. Colin recently joined Amylyx Pharmaceuticals as the Head of Medical Affairs in Germany in 2022. Prior to that, they worked at Roche, where they held various roles, including Retirement, Medical Director in Specialty Care, and Medical Director in Neuroscience from 2017 to 2022. Colin also worked as a Medical Director for Gilead Sciences from 2016 to 2017. Before that, they had positions at Biogen as the EU Regional Medical Director and Medical Director in Germany from 2001 to 2016. Colin started their career as a Medical Director at ArztPartner almeda AG in 1999, followed by roles as a Senior Medical Advisor at Bristol-Myers Squibb and Sanofi from 1999 to 1997. Colin began their residency as a Board Certified Internist at Rotkreuzklinikum München GGmbH in 1988, which lasted until 1997.

Colin Wernsdoerfer's education history includes attending the Technical University of Munich, Università degli Studi di Parma, and the University of Cologne. However, specific degree names and fields of study are not provided.